Aardvark Therapeutics, Inc.
aardvarktherapeutics.comWhat Do They Do?
Develops small-molecule drug candidates targeting gut bitter taste receptors for people with hunger-related conditions, including Prader-Willi syndrome and other metabolic diseases.
10-K for FY2025, filed Mar 23, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$14.4MView ↗
- ▲ 0% (Loss)
- vs −$14.4M in Q2 FY2025
-
Aug 11, 2026
Company terminated the HERO and OLE trials
It does not currently intend to resume them as previously designed.
Sources
8-K, filed Aug 11, 2026
Aardvark is assessing the unblinded clinical data accumulated to date across both the HERO (Hunger Elimination or Reduction Objective)…View ↗
-
May 14, 2026
FDA placed ARD-101 under a full clinical hold
The hold covers all ongoing studies under the application, including the HERO and OLE trials.
Sources
8-K, filed May 14, 2026
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage…View ↗
Who Do They Compete With?
Competes with Soleno Therapeutics, Rhythm Pharmaceuticals, Relmada Therapeutics, and Bright Minds Biosciences
10-K for FY2025, filed Mar 23, 2026With respect to ARD-101, VYKAT XR from Soleno Therapeutics is the only FDA-approved treatment for hyperphagia in patients with PWS. We are…View ↗
Loading...
